[{"orgOrder":0,"company":"SK Bioscience","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Matrix-M","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"SK Bioscience \/ Novavax","highestDevelopmentStatusID":"10","companyTruncated":"SK Bioscience \/ Novavax"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2021","type":"Expanded Collaboration","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"SK Bioscience \/ Novavax","highestDevelopmentStatusID":"10","companyTruncated":"SK Bioscience \/ Novavax"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"PCV21 vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"SK Bioscience \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"SK Bioscience \/ Sanofi"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The collaboration aims to develop, license, and commercialize GBP410 (PCV21 vaccine) for both pediatric and adult populations, reaffirming their commitment to fighting pneumococcal disease.

                          Product Name : GBP410

                          Product Type : Vaccine

                          Upfront Cash : $52.0 million

                          December 23, 2024

                          Lead Product(s) : PCV21 vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Sanofi

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Skycovion,a vaccine for protecting against Covid-19 has small particles known as nanoparticles containing parts of the spike protein found on the surface of SARS-CoV-2.

                          Product Name : Skycovion

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          August 20, 2022

                          Lead Product(s) : COVID-19 Vaccine Recombinant, Adjuvanted,Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Top-line results also showed CT-P59 to have a positive safety profile, with no clinically meaningful differences between patients treated with CT-P59 (40mg/kg) and placebo-treated patients.

                          Product Name : Regkirona

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          June 14, 2021

                          Lead Product(s) : Regdanvimab

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Regdanvimab is a monoclonal antibody with activity against COVID-19. A monoclonal antibody is a type of protein that has been designed to attach to a specific structure (called an antigen).

                          Product Name : Regkirona

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          February 24, 2021

                          Lead Product(s) : Regdanvimab

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : SK Bioscience will add significant production capacity under this new agreement. Novavax recently reported positive interim efficacy results for the NVX-CoV2373 in an ongoing Phase 3 trial in the U.K and is also currently conducting a Phase 3 trial in th...

                          Product Name : Nuvaxovid

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          February 15, 2021

                          Lead Product(s) : NVX-COV2373,Matrix-m1

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Novavax

                          Deal Size : Undisclosed

                          Deal Type : Expanded Collaboration

                          blank